Peregrine, U.S. Department of Defense infectious news

Peregrine said the DoD's Defense Threat Reduction Agency (DTRA) extended the two-year base period of a 2008 contract by six months to March 2011 to continue development of bavituximab and PGN635 to treat viral hemorrhagic fever (VHF). The biotech will receive an additional $2.4 million for the extension.

Peregrine is developing bavituximab and PGN635 for VHF under FDA's Animal Rule, which allows marketing approval to be granted based on efficacy in relevant animal models and an acceptable safety risk profile in humans (see BioCentury, July 7, 2008). ...